NeoGenomics, Inc. (NEO) vs NeuroPace, Inc. (NPCE)
A side-by-side comparison of NeoGenomics, Inc. and NeuroPace, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NEO
NeoGenomics, Inc.
$16.57HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
NPCE
NeuroPace, Inc.
$12.77HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — NEO vs NPCE
growth of $100 · dividends reinvested · last 5yNEO -60.1% (-16.8%/yr)NPCE -47.0% (-11.9%/yr)NPCE compounded faster over this window
NEO NPCE
NEO vs NPCE: by the numbers
- •NPCE is the larger company ($435M vs $426M market cap).
- •Both run net losses; NEO's is the smaller (-6.77% vs -19.34% net margin).
- •NPCE grew revenue faster over the past five years (15.85% vs 9.41% CAGR).
Metrics side by side
Valuation
| Metric | NEO | NPCE |
|---|---|---|
| Forward P/E | 90.65 | N/A |
| P/S ratio | 0.56 | 4.41 |
| P/B ratio | 0.54 | 36.64 |
Profitability
| Metric | NEO | NPCE |
|---|---|---|
| Gross margin | 42.92% | 79.63% |
| Operating margin | -8.63% | -15.26% |
| Net margin | -6.77% | -19.34% |
| ROE | -6.60% | -160.85% |
| ROIC | -5.29% | -18.95% |
Growth (annualized)
| Metric | NEO | NPCE |
|---|---|---|
| Revenue CAGR (5Y) | 9.41% | 15.85% |
| Total return CAGR (5Y) | -15.14% | -4.94% |
Frequently asked
- Which has grown faster, NEO or NPCE?
- Over the past five years, NPCE grew revenue faster — NEO at a 9.41% CAGR versus NPCE at 15.85%.
- How have NEO and NPCE total returns compared?
- Over the past 5 years, NEO delivered -15.14% and NPCE delivered -4.94% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
NeoGenomics ROENeuroPace ROENeoGenomics operating marginNeuroPace operating marginNeoGenomics revenue growthNeuroPace revenue growthNeoGenomics free cash flowNeuroPace free cash flow
NeoGenomics & NeuroPace appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.